ELEDON PHARMACEUTICALS INC (ELDN)

Company Profile

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 17 full-time employees. The company went IPO on 2014-09-17. The firm is focused on developing life-changing, targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). The firm's lead compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with a high affinity for CD40 Ligand (CD40L, also called CD154). Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Company Info

ELEDON PHARMACEUTICALS INC

19900 MacArthur Blvd Ste 550

Irvine CALIFORNIA 92612

P: 19492388090

CEO: David-Alexandre C. Gros

Employees: 17

Website: https://eledon.com/